Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 6/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 9/20 | 0.56 |
| ▸ | PGR | P06401 | 5/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SNCA | P37840 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30140884 | 1.00 | SHBG (0.59) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL7703808 | 1.00 | SHBG (0.59) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL12638972 | 0.87 | AR (0.56) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL13474816 | 0.86 | AR (0.55) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL23383533 | 0.85 | SERPINA6 (0.61) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL1650166 | 0.85 | SERPINA6 (0.61) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL29335237 | 0.84 | AR (0.53) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL29335494 | 0.83 | AR (0.51) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL2833823 | 0.83 | AR (0.51) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL4212652 | 0.83 | AR (0.55) | SHBGSERPINA6SLC22A1ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022257895-A1 | INTERMEDIATE FOR PREPARING FULVESTRANT AND PREPARATION METHOD THEREFOR | 上海弼领生物技术有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-20100204497-A1 | Process For The Preparation of 7 alpha-Methylsteroids | N.V. ORGANON | 2010-08-12 | — | — | US | disclosed |
| EP-1470151-B1 | PROCESS FOR THE PREPARATION OF 7-ALPHA-METHYLSTEROIDS | ORGANON NV (NL) | 2009-12-30 | — | — | EP | disclosed |
| US-20050090476-A1 | Process for the preparation of 7alpha-methylsteroids | MERCK SHARP & DOHME B.V. (NL) | 2005-04-28 | — | — | US | disclosed |
| EP-1470151-A1 | PROCESS FOR THE PREPARATION OF 7-ALPHA-METHYLSTEROIDS | Akzo Nobel N.V. (NL) | 2004-10-27 | — | — | EP | disclosed |
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | AKZO NOBEL N.V. (NL) | 2004-10-21 | — | — | US | disclosed |
| US-6756366-B1 | 19-NORTESTOSTERONE DERIVATIVES; ORALLY ACTIVE; HIGH POTENCY | AKZO NOBEL N.V. (NL) | 2004-06-29 | — | — | US | disclosed |
| EP-1212345-B1 | ORALLY ACTIVE 7-ALPHA-ALKYL ANDROGENS | AKZO NOBEL NV (NL) | 2003-08-06 | — | — | EP | disclosed |
| WO-2003059931-A1 | PROCESS FOR THE PREPARATION OF 7α-METHYLSTEROIDS | AKZO NOBEL N.V. (NL) | 2003-07-24 | — | — | WO | disclosed |
| EP-1212345-A2 | ORALLY ACTIVE 7.ALPHA.-ALKYL ANDROGENS | Akzo Nobel N.V. (NL) | 2002-06-12 | — | — | EP | disclosed |
| WO-2000059920-A2 | ORALLY ACTIVE 7.ALPHA.-ALKYL ANDROGENS | AKZO NOBEL N.V. (NL) | 2000-10-12 | — | — | WO | disclosed |
| EP-0280618-B1 | 19-NOR STEROIDS SUBSTITUTED AT POSITION 7, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1992-09-30 | — | — | EP | disclosed |
| EP-0280618-A1 | 19-Nor steroids substituted at position 7, their preparation, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL-UCLAF (FR) | 1988-08-31 | — | — | EP | disclosed |
| US-4073899-A | 7A-METHYL-ESTR-5-ENE-3B,17B-DIOL AND 17-ACYL ESTERS | RICHARDSON-MERRELL, INC. (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090476-A1 | Process for the preparation of 7alpha-methylsteroids | CYP17A1, CYP21A2, HSD17B7 | SHBG 60/4885SERPINA6 527/4885SLC22A1 2240/4885 |
| US-20100204497-A1 | Process For The Preparation of 7 alpha-Methylsteroids | CYP17A1, CYP21A2, HSD17B7 | SHBG 59/4885SERPINA6 549/4885SLC22A1 2824/4885 |
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | NR5A1, AR, SHBG | SHBG 3/4885SERPINA6 466/4885SLC22A1 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.